title: Tyrosine kinase inhibitors and pregnancy.
abstract: The management of patients with chronic myeloid leukemia (CML) during pregnancy has become recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of CML patients; in fact, patients diagnosed in chronic phase can reasonably expect many years of excellent disease control and good quality of life, as well as a normal life expectancy, including the necessity to address issues relating to fertility and pregnancy. Physicians are frequently being asked for advice regarding the need for, and/or the appropriateness of, stopping treatment in order to conceive. In this report, we will review the data published in terms of fertility, conception, pregnancy, pregnancy outcome and illness control for TKI treated CML patients, as well as how to manage a planned and/or unplanned pregnancy.
authors.affiliation: Hematology, S. Eugenio Hospital, Tor Vergata University.
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Abruzzese
authors.affiliation: Hematology, S. Eugenio Hospital, Tor Vergata University.
authors.forename: Malgorzata Monika
authors.initials: MM
authors.lastname: Trawinska
authors.affiliation: Hematology, S. Eugenio Hospital, Tor Vergata University.
authors.forename: Alessio Pio
authors.initials: AP
authors.lastname: Perrotti
authors.affiliation: Hematology, S. Eugenio Hospital, Tor Vergata University.
authors.forename: Paolo
authors.initials: P
authors.lastname: De Fabritiis